Deadline Date: April 13, 2026
The CHISEL Healthcare InnoMatch Prize 2026 is calling for innovative, market-ready or near market-ready solutions to address critical and emerging healthcare needs.
The challenge focuses on enhancing health through an AI and tech-enabled workforce, leveraging AI and technology to transform the healthcare workforce, creating a holistic care delivery system across all care settings and patient touchpoints, driving productivity gains, improving cost efficiency, and delivering significantly improved health outcomes for patients.
Organised by the Centre of Healthcare Innovation (CHI), presented by Temasek Foundation, and supported by the Ministry of Health Singapore, CHISEL is a cross-cluster platform that accelerates the adoption of solutions from start-ups and SMEs by matching market-ready innovations to public healthcare needs. Through a structured end-to-end process, participants can access centralised funding, standardised evaluation, and opportunities to pilot their solutions within operational healthcare environments.
The Healthcare InnoMatch 2026 initiative is conducted in partnership with SingHealth, the National University Health System (NUHS), and NHG Health. Successful proposals will receive funding support of up to S$500,000 each, a place in the CHI Start-up Enterprise Link program for test-bedding and collaboration, and cross-cluster evaluation with potential adoption by partner healthcare clusters.
Eligible participants include start-ups and SMEs, locally or internationally based, with annual revenues below S$100 million. Research institutions or innovation units may participate if they are subsidiaries. Participants must demonstrate proof of registration and professional insurance and must not be in exit negotiations during the challenge and test-bedding phases.
Solutions submitted should have a high level of market readiness, seek to deliver improved patient health outcomes and experience, and relate directly to operational processes impacting patient care. They may originate from within or outside Singapore but must be evaluated within one of the three healthcare clusters. Preference will be given to solutions with relevant regulatory compliance, licensing, and prior demonstration of clinical efficacy. Early-stage research studies, minimally viable products, or solutions still in development will not be accepted.
For more information, visit Centre of Healthcare Innovation.
